Diversified Trust Co Cuts Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Diversified Trust Co lessened its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 7.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 36,601 shares of the medical device company’s stock after selling 3,130 shares during the period. Diversified Trust Co owned about 0.08% of AtriCure worth $1,119,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ATRC. Hood River Capital Management LLC purchased a new stake in AtriCure during the second quarter worth $40,422,000. First Light Asset Management LLC lifted its stake in shares of AtriCure by 42.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company’s stock worth $44,736,000 after purchasing an additional 581,843 shares during the last quarter. Millennium Management LLC boosted its position in AtriCure by 132.5% during the second quarter. Millennium Management LLC now owns 952,765 shares of the medical device company’s stock valued at $21,694,000 after purchasing an additional 543,023 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in AtriCure by 151.6% in the third quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company’s stock valued at $6,425,000 after purchasing an additional 138,046 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in AtriCure by 31.5% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after purchasing an additional 119,929 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Trading Up 2.9 %

Shares of NASDAQ:ATRC opened at $33.66 on Thursday. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $39.04. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -40.55 and a beta of 1.42. The business has a 50-day moving average price of $33.88 and a 200-day moving average price of $28.33.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. The business had revenue of $115.91 million during the quarter, compared to analysts’ expectations of $112.23 million. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The business’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.20) EPS. Equities analysts predict that AtriCure, Inc. will post -0.72 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Oppenheimer raised their price target on shares of AtriCure from $32.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group raised their target price on shares of AtriCure from $53.00 to $61.00 and gave the company a “buy” rating in a research note on Monday, December 9th. StockNews.com raised AtriCure from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. UBS Group raised their price objective on AtriCure from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Needham & Company LLC upped their target price on AtriCure from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.